Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Mutational architecture and clonal heterogeneity in myelofibrosis: Prognostic role of variant type and acquisition sequence

Fiorenza Vanderwert, Valentina Boldrini, Camilla Ghetti et al. Nov 03, 2025 pp. 3760-3760 10.1182/blood-2025-3760

Abstract BACKGROUND: The spectrum of somatic mutations of myeloid-associated genes in patients (pts) with myelofibrosis (MF) has been extensi...

IgD-related AL amyloidosis: Clinical features and outcomes

Sarika Gurnani, Andrew Staron, John Mark Sloan et al. Nov 03, 2025 pp. 7500-7500 10.1182/blood-2025-7500

Abstract Background: Immunoglobulin D (IgD)-related AL amyloidosis is a rare subtype, representing approximately 1% of AL amyloidosis cases,...

Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia

Sadiksha Adhikari, Philipp Sergeev, Nemo Ikonen et al. Nov 03, 2025 pp. 3490-3490 10.1182/blood-2025-3490

Abstract Although patients with acute myeloid leukemia (AML) initially respond to standard chemotherapy, the relapse rate is high, and many...

Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenström macroglobulinemia

Cristina Frusteri, Aleix Real, Ferran Nadeu et al. Nov 03, 2025 pp. 1774-1774 10.1182/blood-2025-1774

Abstract Waldenström Macroglobulinemia (WM) is an incurable lymphoid malignancy characterized by a spectrum of differentiation states from c...

Changes in complete blood count (CBC) and white blood cell (WBC) differential associated with overweight and obesity: A patient-level meta-analysis of randomized trials

Jenyvette Hsia, Ella Derkzen, Benjamin Chin-Yee et al. Nov 03, 2025 pp. 1094-1094 10.1182/blood-2025-1094

Abstract Introduction: Obesity is a global public health concern associated with multiple comorbidities and adverse health outcomes. Hematol...

Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: Updated results of the phase II study

Zhiming Li, Peng Sun, Kaiyang Ding et al. Nov 03, 2025 pp. 3639-3639 10.1182/blood-2025-3639

Abstract Background Relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL) is an aggressive and heterogeneous malignancy without stan...

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

Lukas Scheller, Xiang Zhou, Markus Kreuz et al. Nov 03, 2025 pp. 809-809 10.1182/blood-2025-809

Abstract Hematotoxicity with prolonged cytopenia is the most relevant high-grade toxicity after chimeric antigen receptor (CAR)-T therapy. I...

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study

Giovanni Manfredi Assanto, Silvia Sorella, Giovanni Marsili et al. Nov 03, 2025 pp. 5402-5402 10.1182/blood-2025-5402

Abstract Introduction: In Italy, Brentuximab vedotin (Bv) with AVD (adriamycin, vinblastine, dacarbazine) received approval for the first-li...

Retrospective cohort analysis of treatment patterns and bleeding outcomes in the Korean bleeding disorder registry (KBDR)

Jung Woo Han, Hee Jo Baek, Young-Shil Park et al. Nov 03, 2025 pp. 4853-4853 10.1182/blood-2025-4853

Abstract Background Hemophilia is a rare congenital bleeding disorder characterized by the deficiency of clotting factor...

The impact of voxelotor on the reduction in red blood cell transfusions in US patients with sickle cell disease

Patricia Prince, Carmine Colavecchia, David Purdie et al. Nov 03, 2025 pp. 6530-6530 10.1182/blood-2025-6530

Abstract Background: The current treatment landscape for SCD is limited, and treatment options have associated risks and can be burdensome f...

Thrombocytosis in transient abnormal myelopoiesis: Association with megakaryocytic skewing and GATA1 mutation patterns

Satoshi Saida, Tsutomu Toki, Ritsuko Shimizu et al. Nov 03, 2025 pp. 773-773 10.1182/blood-2025-773

Abstract Background & Objectives: Transient abnormal myelopoiesis (TAM) is a unique neonatal hematological disorder associated with Down...

Thromboembolism and event-free survival in children with extracranial solid tumors: A report from CYP-c.

Stella LeChasseur, David Simonyan, Emma Macdonald et al. Nov 03, 2025 pp. 706-706 10.1182/blood-2025-706

Abstract Background: Thromboembolism (TE) is a known complication in pediatric oncology patients. While its adverse prognostic impact on sur...

SMARCC1 loss impairs differentiation and enhances self-renewal in ASXL1-mutant hematopoietic cells

Taiki Ishida, Toshiya Hino, Hiroki Hayashida et al. Nov 03, 2025 pp. 5008-5008 10.1182/blood-2025-5008

Abstract Additional sex combs-like 1 (ASXL1) is a histone modifier regulating hematopoiesis. Its mutations are common in secondary acute mye...

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe-Paganon et al. Nov 03, 2025 pp. 3611-3611 10.1182/blood-2025-3611

Abstract Introduction: CD20, encoded by MS4A1, is one of the earliest and most extensively used therapeutic targets in B-cell malignancies. I...

Targeting the methylome in T-LGL leukemia: Pre-clinical analysis and Results of a Phase I trial with oral 5-azacytidine

Jonathan Brammer, Zachary Braunstein, Patrick Stevens et al. Nov 03, 2025 pp. 890-890 10.1182/blood-2025-890

Abstract Epigenetic dysregulation, particularly changes in DNA methylation, are major contributors to the onset and progression of Large Gra...

Impact of central nervous system prophylaxis on survival outcomes in patients with primary testicular diffuse large B-cell lymphoma: A single-center analysis

Qirui Zhou, Jinlin Chen, Yihua Pang et al. Nov 03, 2025 pp. 7187-7187 10.1182/blood-2025-7187

Abstract Introduction Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by a high risk of relapse...

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

Qiling Bu, Yiwen Jiang, Jingjing Deng et al. Nov 03, 2025 pp. 7564-7564 10.1182/blood-2025-7564

Abstract Background:Primary plasma cell leukemia (pPCL) is the most aggressive malignancy of plasma cell neoplasms, with a median overall su...

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

Seung-Hwan Lee, Daehun Kwag, Gi June Min et al. Nov 03, 2025 pp. 5149-5149 10.1182/blood-2025-5149

Abstract Background: Recent advances in molecular cytogenetic profiling of B-cell precursor acute lymphoblastic leukemia...

Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial

Harry Erba, Jes Hansen, Sudhir Unni et al. Nov 03, 2025 pp. 2650-2650 10.1182/blood-2025-2650

Abstract Introduction: The global, randomized, placebo (Pbo)-controlled, phase 3 QuANTUM-First trial (NCT02668653) evaluated quizartinib (Qu...

Nanobody-based CD19/CD20 bispecific CAR-T achieves durable remissions in r/r NHL patients

Na Kuang, Shuyu Qiang, Lin Wang et al. Nov 03, 2025 pp. 3724-3724 10.1182/blood-2025-3724

Abstract Background: While CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in relapsed/ref...

Clinical characteristics and whole-exome sequencing-based genomic profiling of post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation

Tatsuro Hirao, Daisuke Kaji, Yuki Shimizu et al. Nov 03, 2025 pp. 1760-1760 10.1182/blood-2025-1760

Abstract Background: Post-transplant lymphoproliferative disorder (PTLD) is a lymphoid neoplasm that arises in the context of immunosuppress...

Integrated analysis of autoantibody profiles and clonal distribution of RAS mutations in juvenile myelomonocytic leukemia

Manabu Wakamatsu, Lili Kotmayer, Masanori Yoshida et al. Nov 03, 2025 pp. 3834-3834 10.1182/blood-2025-3834

Abstract Background: Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive myelodysplastic/myeloproliferative neoplasm occurring i...

Social vulnerability predicts higher county-level pulmonary embolism mortality in the United States : A 2016-2020 nationwide analysis

Ayushi Garg, Jahnavi Gollamudi Nov 03, 2025 pp. 4469-4469 10.1182/blood-2025-4469

Abstract Introduction: Pulmonary Embolism (PE) remains a leading cause of mortality in adults in U.S. contributing to an estimated 100,000 c...

Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers

Holly Lee, Sungwoo Ahn, Deeksha Vishwamitra et al. Nov 03, 2025 pp. 1030-1030 10.1182/blood-2025-1030

Abstract Bispecific T cell engagers (TCE) have led to significant therapeutic advances in multiple myeloma (MM), however with finite durabil...

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Roberta S. Azevedo, Nicholas Short, Alex Bataller et al. Nov 03, 2025 pp. 997-997 10.1182/blood-2025-997

Abstract Background: Patients (pts) with FLT3-mutated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy (IC) or wit...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page